Literature DB >> 1617667

p53 mutations occur in aggressive breast cancer.

R Mazars1, L Spinardi, M BenCheikh, J Simony-Lafontaine, P Jeanteur, C Theillet.   

Abstract

Using a polymerase chain reaction-single strand conformation polymorphism approach we analyzed 96 human primary breast tumors for the presence of mutations in exons 2, 5, 6, 7, 8, and 9 of the p53 gene. These exons have been shown to comprise highly conserved sequences and the portion including exons 5 through 9 is believed to be the target for over 90% of the acquired mutations in human cancer. Eighteen tumors of the 96 (18.7%) tested showed reproducibly a variant band indicative of a mutation. Most (15 tumors) of the mutations were single nucleotide substitutions and G:C to A:T transitions were prevalent (6 tumors), G:C to T:A transversions came next (4 tumors), and guanines were always on the nontranscribed strand. Concomitant loss of the wild type allele and mutation of the other copy was observed in only 3 of 18 mutated cases; this is consistent with the heterogeneous cellular composition of breast tumors. Furthermore p53 mutations were correlated to estrogen and/or progesterone receptor negative tumors, thus indicating their relationships to aggressive breast cancer. No association could be observed with DNA amplification events in these tumors.

Entities:  

Mesh:

Year:  1992        PMID: 1617667

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases.

Authors:  Farah Jouali; Fatima Zahra El Ansari; Nabila Marchoudi; Amina Barakat; Hassaniya Zmaimita; Hamza Samlali; Jamal Fekkak
Journal:  Int J Mol Epidemiol Genet       Date:  2020-06-15

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

Review 3.  The p53 tumor suppressor gene in breast cancer.

Authors:  R M Elledge; D C Allred
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice.

Authors:  J Lawler; W M Miao; M Duquette; N Bouck; R T Bronson; R O Hynes
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 5.  Familial breast cancer and genes involved in breast carcinogenesis.

Authors:  A Lindblom
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

6.  Novel pattern of P53 mutation in breast cancers from Austrian women.

Authors:  A Hartmann; G Rosanelli; H Blaszyk; J M Cunningham; R M McGovern; J J Schroeder; D J Schaid; J S Kovach; S S Sommer
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

7.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

8.  p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer.

Authors:  I Brotherick; B K Shenton; W K Cowan; B Angus; C H Horne; M J Higgs; T W Lennard
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

9.  Prognostic significance of p53 gene alterations in node-negative breast cancer.

Authors:  R M Elledge; S A Fuqua; G M Clark; P Pujol; D C Allred; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases.

Authors:  G MacGrogan; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.